Pyogenic granuloma: giai đoạn mao mạch

The Histological and Molecular Landscape of Pyogenic Granuloma: An In-Depth Analysis of the Capillary-Vascular Stage

Section 1: Definitional Clarity: From "Pyogenic Granuloma" to "Lobular Capillary Hemangioma"

1.1. Deconstructing the Historical Misnomer

The term "pyogenic granuloma" (PG) is a widely recognized and persistent clinical designation for a common vascular lesion of the skin and mucous membranes.1 However, this terminology is a deeply entrenched historical misnomer that is both "inaccurate" and biologically misleading.1 The name is flawed on two fundamental counts. Firstly, the lesion is not "pyogenic," a term meaning pus-producing.3 Histopathological analysis confirms that pyogenic granulomas are "rarely related to infection" and do not generally contain pus or organized collections of white blood cells (abscesses).3 While a mixed inflammatory infiltrate is a common component of the stroma, it is a secondary feature, not a primary infectious or pyogenic process.1 Extensive investigations have consistently "failed to identify a definite infectious agent as a trigger".2 Secondly, the lesion is not a true "granuloma".4 In strict pathological terms, a granuloma is a specific, organized aggregation of macrophages, often with a surrounding infiltrate of lymphocytes.2 The pyogenic granuloma lacks this defining structure. The confusion that led to this misnomer likely stems from the lesion's earliest developmental stage, the "cellular phase," in which it is "histologically identical to granulation tissue".6 This early phase, a non-specific proliferation of capillaries and inflammatory cells in an edematous matrix, mimics a standard wound-healing response.4 This histological resemblance to granulation tissue is the probable origin of the "granuloma" misnomer, which has persisted despite a modern understanding of the lesion's true nature.2 This persistence creates a significant "terminology-biology gap." The name "pyogenic granuloma" primes the non-specialist clinician to consider an infectious or exaggerated inflammatory etiology 2, potentially obscuring the lesion's true vascular and, in many cases, neoplastic pathogenesis.

1.2. Establishing the Accurate Terminology: Lobular Capillary Hemangioma (LCH)

The scientifically accurate and descriptively precise term for this entity is "Lobular Capillary Hemangioma" (LCH).1 This name is derived directly from the lesion's pathognomonic (diagnostically characteristic) features, which become apparent during its "capillary-vascular stage." The lesion is, by definition, a "capillary hemangioma of lobular subtype".4 Microscopic examination of the mature lesion reveals a "prominent lobular capillary arrangement" 1 within the dermis. This architecture is the defining feature of the "capillary stage" and is the central focus of this analysis. Therefore, LCH is correctly defined as a "benign (not cancer) blood vessel tumor".1 The reclassification of LCH/PG from a "reactive hyperplasia" (a term still found in some literature 5) to a "benign vascular tumor" 2 represents a fundamental paradigm shift in its pathobiological understanding. This shift is not merely semantic; it is propelled by modern molecular evidence that has identified oncogenic driver mutations in a significant subset of these lesions.16 This molecular data recasts the well-known "triggers," such as trauma and hormonal changes. These factors are increasingly understood not as the sole cause of a reactive process, but rather as initiators or promoters of a true, albeit benign, neoplastic proliferation. For example, trauma may be the event that induces the specific, localized, "trauma-induced genetic mutations" that give rise to the tumor.20

1.3. Associated Synonyms and Clinical Variants

To ensure comprehensive understanding, it is important to recognize other terms used for this lesion. In some dermatological literature, it has been referred to as "granuloma telangiectaticum," a name highlighting the presence of numerous dilated blood vessels (telangiectasias).21 A critical and common clinical variant is "granuloma gravidarum," also known as the "pregnancy tumor" or "epulis gravidarum".1 This term is reserved specifically for LCH lesions that arise on the mucous membranes—most frequently the gingiva (gums)—in pregnant women.1 These lesions, which are histologically identical to LCH, are estimated to occur in up to 5% of pregnancies 21 and typically appear during the second or third trimester, coinciding with peak hormonal changes.2

Section 2: Etiopathogenesis and Clinical Synopsis

2.1. Etiological Triggers: A Triad of Causes

While the precise, ultimate cause of LCH/PG remains unknown in many spontaneous cases 3, its development is strongly associated with a triad of precipitating factors: trauma, hormonal changes, and iatrogenic (drug-induced) stimuli.

• Trauma: Minor, localized trauma or chronic irritation is a well-established trigger.3 This can include minor injuries, skin piercings, poor oral hygiene, or chronic rubbing.3 The lesion often appears at the site of a recent injury.25 While this association is strong, some studies suggest that a clear history of preceding trauma is only identifiable in a minority of cases, perhaps as few as 7%.2
• Hormonal Influence: Hormonal fluctuations are a major pathogenic factor, particularly in the development of mucosal lesions.10 The classic example is the "granuloma gravidarum," which arises during pregnancy.3 It is theorized that the elevated circulating levels of estrogen and progesterone during pregnancy act as pro-angiogenic factors, promoting the development and exuberant growth of these vascular lesions.22 This hormonal influence also helps explain the higher incidence of mucosal LCH in females, particularly during their childbearing years.24
• Iatrogenic/Drug-Induced: A significant and growing number of LCH/PG cases are iatrogenic, arising as a cutaneous adverse effect of various medications.2 The list of implicated drugs is extensive and includes:
• Systemic and Topical Retinoids: (e.g., isotretinoin, acitretin).2
• Antiretrovirals: (e.g., the protease inhibitor indinavir).2
• Antineoplastics: (e.g., systemic 5-fluorouracil, capecitabine, and taxanes like docetaxel and paclitaxel).2
• Targeted Cancer Therapies: Epidermal Growth Factor Receptor (EGFR) inhibitors (e.g., cetuximab, gefitinib, erlotinib) are a common cause of multiple periungual (around the nail) PGs.2
• Immunosuppressive Agents: (e.g., cyclosporine and tacrolimus), particularly in hematopoietic stem cell transplant recipients.2

The association of LCH/PG with a specific class of targeted therapies—selective BRAF inhibitors (e.g., vemurafenib, encorafenib) 29—is profoundly illuminating. This is not merely another drug side effect; it provides a human in vivo model that validates the modern molecular hypothesis of LCH. These drugs are designed to block the Mitogen-Activated Protein Kinase (MAPK) pathway in cancer cells that harbor a specific BRAF mutation. However, in BRAF wild-type cells, such as normal skin, these drugs are known to cause a "paradoxical activation" of this same pathway.30 The fact that these specific drugs induce the formation of LCH lesions is powerful, direct evidence that LCH pathogenesis is, at its core, driven by activation of the MAPK pathway. This single clinical observation provides a causal bridge, linking the iatrogenic (drug-induced) and sporadic (mutation-driven) forms of LCH under a single, unified molecular mechanism.16

2.2. Clinical Presentation: The Macroscopic Correlate of the Capillary Stage

The clinical presentation described here is that of the mature, fully developed "capillary/vascular stage" of the lesion.

• Growth: The most alarming feature for patients is its "rapid exophytic growth".2 The lesion appears to "grow quickly" 7, often evolving from a small spot to a considerable nodule over a period of days to weeks.1
• Appearance: Clinically, LCH/PG presents as a "raised, bright red" 9, "fleshy" papule or nodule.1 Its surface texture is often described with evocative terms, such as "raspberry-like" or having a "raw minced meat" appearance.21 While "bright red" is the classic description due to the high vascularity, the color can range from pink to a darker reddish-brown or purple.3
• Surface and Base: The lesion's surface, which may be smooth in its earliest phase 1, frequently becomes "bumpy," crusted, or "ulcerated".1 The lesion's base of attachment to the skin or mucosa can be "pedunculated," meaning it is attached by a stalk-like structure 1, or "sessile," indicating it is attached by a broad, flat base.1 A very common and characteristic diagnostic sign is a "scaly, white collarette" of epidermis surrounding the base of the lesion.2
• Hallmark Symptom: Friability and Bleeding: This is the lesion's most defining clinical characteristic and the primary reason patients seek treatment. The lesion is exceptionally "friable".2 This means the tissue is delicate and tears with minimal friction. Consequently, the lesion "bleeds easily" and often "profusely".1 This "nuisance bleeding" can be brisk, difficult to stop, and disproportionate to the minor trauma that incites it.21

Section 3: The Natural Course: Histological Staging of Lobular Capillary Hemangioma

3.1. A Framework for Lesion Evolution: The Three-Phase Model

The histopathological presentation of Lobular Capillary Hemangioma is not static; it is a dynamic process that evolves. The natural course of this lesion can be categorized into three distinct, sequential histological phases.29 This framework is essential for understanding the query, as the "capillary/vascular stage" is the mature, central phase of this life cycle. The three phases are: 1. (i) The Cellular Phase (Early/Proliferative Stage) 2. (ii) The Capillary/Vascular Phase (Mature/Lobular Stage) 3. (iii) The Involutionary Phase (Fibrotic/Healing Stage) A correct histopathological diagnosis requires an understanding of this progression, as the microscopic appearance of the lesion changes dramatically depending on when in its life cycle it is biopsied.

3.2. Phase I: The "Cellular Phase" (Early/Proliferative Stage)

This is the initial, "early phase" of the lesion's development.37 Clinically, this stage corresponds to the "small pinhead-sized red…spot" 21 that has just begun to form. Histologically, this phase is defined by a "diffuse" proliferation of "endothelial cells".37 These cells are just beginning to organize, with "few budding into capillaries".37 This is the stage that is the source of the "granuloma" misnomer. In this early form, the lesion is described as "histologically identical to granulation tissue".6 It consists of a non-specific proliferation of new blood vessels, a significant inflammatory cell infiltrate (including lymphocytes, neutrophils, and mast cells) 2, and an "edematous matrix" (a swollen, fluid-filled stroma).6 A biopsy taken at this precise moment would be very difficult, if not impossible, to distinguish from a simple, exuberant wound-healing response.4

3.3. Phase II: The "Capillary/Vascular Phase" (Mature Stage)

This is the fully developed, "classic" LCH, and the primary subject of this analysis. It corresponds to the clinical picture described in Section 2.2: the rapidly grown, red, fleshy, bleeding nodule.1 This phase represents the critical "switch" that reveals the lesion's true, organized nature. The proliferating endothelial cells and vessels, which were diffuse and disorganized in Phase I, now mature and organize themselves into the pathognomonic lobular architecture.2 This architectural shift is the single most important diagnostic event. If the lesion were merely reactive granulation tissue (as in Phase I), it would simply mature into a fibrous scar. Instead, it transitions from the "Cellular Phase" into this highly structured "Capillary Phase," demonstrating a specific, organized, and neoplastic growth pattern.2 This transformation is the morphological evidence of the lesion's evolution from a reactive-like nidus into a true benign tumor.

3.4. Phase III: The "Involutionary Phase" (Fibrotic/Healing Stage)

This is the "final stage of regression" or healing for the lesion.6 It is the histological endpoint of the LCH life cycle. Microscopically, this phase is defined by "extensive fibrosis in the connective tissue".37 The stroma, which was edematous in Phase I and fibromyxoid in Phase II, transitions to being dominated by "densely packed type I collagen".22 As this fibrosis occurs, the vascular components and inflammatory infiltrate "disappear" or regress significantly.22 Older lesions are therefore characterized by this prominent "fibrous character".4 Clinically, this histological change corresponds to the lesion losing its bright red, fleshy, and friable state. It becomes a "paler pink colour" 1 and evolves into a firmer, non-bleeding, fibrous nodule.

Table 1. Summary of the Three Histological Phases of Lobular Capillary Hemangioma

Phase Key Clinical Features Key Histological Features Phase I: Cellular Phase Small, "pinhead-sized" red papule.21 Histologically "identical to granulation tissue".6 Diffuse endothelial cells, few budding capillaries.37 Edematous stroma/matrix.6 Inflammatory cell infiltration.22 Phase II: Capillary/Vascular Phase Rapidly growing, bright red, "fleshy" nodule.1 "Raspberry-like" or "raw minced meat" appearance.21 Extremely friable; bleeds profusely with minor trauma.35 Often has an epidermal "collarette" at the base.3 Pathognomonic "prominent lobular capillary arrangement".1 Plump endothelial cells lining capillaries.29 Lobules separated by a "fibromyxoid stroma".22 Thinned or ulcerated overlying epidermis.1 Phase III: Involutionary Phase Lesion becomes a "paler pink colour".1 Firmer, less friable, more fibrous nodule. May spontaneously regress (especially "granuloma gravidarum" post-partum).1 "Extensive fibrosis" in the connective tissue.6 Stroma contains "densely packed type I collagen".22 Vascularity and inflammation regress; myofibroblasts disappear.22

Section 4: Exhaustive Analysis of the Capillary (Vascular) Stage

The Capillary/Vascular Phase (Phase II) is the definitive, mature state of the Lobular Capillary Hemangioma. Its histopathological features are unique and directly explain its dramatic clinical presentation.

4.1. Clinical Correlation: The Histopathology Made Manifest

The microscopic structure of the capillary stage is the direct cause of its macroscopic appearance and symptoms. The "prominent lobular capillary arrangement" 1 and the mass of "highly vascular granulation tissue" 4 that compose the core of the lesion are what give it the characteristic "bright red, fleshy" clinical appearance.13 Most importantly, the hallmark clinical symptom—extreme friability and profuse bleeding 13—is a direct consequence of the microscopic structure. The highly vascular, delicate lobules are covered by an epidermis that is markedly "thinned" and often "ulcerated".1 This leaves minimal protective tissue between the environment and the "proliferating capillaries" 4 just beneath the surface, making profuse hemorrhage from minor trauma inevitable.

4.2. The Definitive Histological Architecture: The Lobule

The pathognomonic feature of this stage is the "lobular capillary hemangioma" pattern.1 On low-power microscopy, the lesion is typically seen as a "well-circumscribed" 39 and "exophytic, polypoid mass" 2, meaning it is a well-defined, mushroom-shaped growth protruding from the skin surface. This mass is composed of "lobular aggregates of capillary-sized vessels".2 These aggregates are often described as "tufts of thin-walled capillaries".2 These lobules, which are the fundamental unit of the tumor, are separated from each other by intervening "fibrous septa" 40 or a "fibromyxoid stroma".2 A critical architectural feature, often seen on careful examination, is the presence of a "central feeder vessel" within each lobule 2, from which the smaller capillaries appear to radiate. This specific architecture provides a clear "blueprint" for the lesion's notorious clinical behavior, especially its high recurrence rate. The "thinned/ulcerated epidermis" 1 over "proliferating capillaries" 4 explains why it bleeds.36 The "polypoid mass" 2 on a "fibrovascular stalk" 2 containing these "central feeder vessels" 2 explains why it recurs. Any treatment that is too superficial, such as a simple shave biopsy, curettage, or electrodesiccation 2, may remove the exophytic lobules but leave behind the stalk and feeder vessels at the base. This incomplete removal is the primary reason the "problem will come back" 25 and why "recurrence is common".1 The histopathology, therefore, dictates the necessary treatment: "complete primary excision" 2 that includes the base of the lesion.6

4.3. Cytological Detail: Endothelial Cells and Stroma

A high-magnification view reveals specific cellular details within the capillary stage.

• Endothelial Cells: The proliferating capillaries are lined by characteristic "plump endothelial cells".2 A distinct histological gradient is often observed from the top of the lesion to its base 2:
• In the superficial regions of the lesion (closer to the epidermis), the lobules are "more distinctive" and well-formed. The endothelial cells lining them are "flattened to slightly plump".2
• In the deeper parts of the lesion (near the base), there is "increased cellularity." The endothelial cells become more numerous, are "overlapping," and can form more solid-looking sheets of cells. This increased density results in "small and indistinct lumens".2
• Mitotic Activity: Reflecting the rapid clinical growth, "mitotic activity" (cells in the process of dividing) is "highly variable".2 Mitotic figures can be "frequent".39 However, the cells themselves are bland and lack atypia (they do not look cancerous), which is a key feature in distinguishing LCH from malignancies like angiosarcoma.39
• Stromal Composition: The connective tissue between the lobules is an active component, not just inert "stuffing." It is variously described as:
• "Edematous" (swollen with fluid) 33, particularly in lesions that are still maturing from Phase I.6
• "Fibromyxoid," indicating a mix of fibrous tissue and mucoid (mucin-rich) ground substance.2
• "Loose fibrous stroma".2
• This stroma also contains a "variegated inflammatory infiltrate".2 This "mixed inflammatory infiltrate" consists of lymphocytes, neutrophils, plasma cells, and mast cells.2

This histological gradient (organized lobules superficially vs. dense, cellular, "indistinct" proliferation deeper 2) is significant. It suggests a "pushing" neoplastic growth model. Simple granulation tissue organizes from the base up as part of a wound-healing process. The findings in LCH describe the opposite: a deep, solid, cellular growth front that appears to mature and organize into the classic "lobules" as it pushes superficially toward the epidermis. This "pushing" growth pattern is more characteristic of a benign neoplasm than a reactive process.

4.4. The Epithelial "Collarette"

At the junction with the normal, unaffected skin (the "base" of the lesion), the epidermis often reacts to the "pushing" growth of the underlying vascular mass. This reaction manifests as "inward growth" of the epidermis 6 or "elongated rete ridges" (the "fingers" of the epidermis that dip into the dermis).1 This "epidermal collarette" 1 is a classic diagnostic feature. It appears to "hug" or "cup" the base of the polypoid mass and is the feature that forms the "scaly, white" ring seen clinically.2

Section 5: Molecular Drivers of the Proliferative Vascular Stage

The rapid, organized proliferation of the capillary stage is not a random event; it is an actively driven process, controlled at the molecular level by specific growth factors and, in many cases, by genetic mutations.

5.1. The Angiogenic Engine: Cytokines and Growth Factors

The vascular proliferation (angiogenesis) of the capillary stage is a hallmark of "inflammatory neovascularization".22 This process is actively "switched on" by a milieu of pro-angiogenic cytokines and growth factors.22 The most notable and well-studied of these is Vascular Endothelial Growth Factor (VEGF).22 Research confirms that "increased VEGF expression" is a key characteristic of LCH/PG.22 VEGF is a potent signal that promotes the survival, proliferation, and migration of endothelial cells, directly "driving" the formation of the new capillary lobules.22 Other factors also play a critical role. Mast cell mediators, such as tryptase, are found in the stroma.2 Tryptase "promotes fibroblast activation, collagen deposition, and fibrosis," helping to build the "granulation tissue" scaffold upon which the new vessels proliferate.22

5.2. A Paradigm Shift: LCH as a Benign Neoplasm

For decades, LCH/PG was debated as a "reactive" process.5 However, recent molecular studies have provided powerful evidence that, in a significant number of cases, LCH/PG is a "benign neoplasm".17 This neoplastic model posits that the "capillary stage" is a true, clonal proliferation. This proliferation is driven by the "constitutive activation of the mitogen-activated protein kinase (MAPK) pathway".16 The MAPK pathway is a primary signaling cascade inside a cell that, when activated, tells the cell to grow and divide. In these LCH lesions, this pathway is "constitutively" active, meaning it is permanently "stuck on," leading to uncontrolled (though benign) proliferation.

5.3. Analysis of Somatic Mutations (The Genetic "Engine")

This "stuck on" signal is often the result of specific, acquired genetic errors known as activating somatic mutations. These mutations have been identified in key genes that make up the MAPK/ERK signaling pathway.16

• BRAF: The BRAF V600E (c.1799T>A) mutation has been identified as a "major driver mutation" in the pathogenesis of LCH/PG.18 This specific mutation is particularly common in PGs that arise secondary to trauma or within preexisting vascular malformations like port-wine stains.41 Immunohistochemical studies have confirmed that the endothelial cells themselves are the carriers of this mutation, making them the neoplastic cell of origin.18 Other studies have also identified this same BRAF V600E (p.Val600Glu) mutation in sporadic LCH of childhood.16
• RAS: BRAF is not the only gene implicated. Activating hotspot mutations have also been found in other upstream genes in the same pathway, including HRAS (e.g., p.Gly13Arg, p.Ala59Thr) 16 and KRAS (e.g., c.37G>C).17
• Other Genes: Mutations in MAP2K1 (a gene "downstream" of RAS and BRAF in the same pathway) have also been reported.16 Investigations into other related genes like GNA11 and GNA14 42 further solidify the central role of the MAPK/ERK signaling cascade as the primary target of these pathogenetic events.

5.4. A Critical Nuance: Contradictory Findings and Site-Specific Pathogenesis

While this molecular evidence is compelling, the picture is complex and not entirely uniform. This analysis must account for crucial, contradictory findings in the research, which point to a more sophisticated, site-specific pathogenesis. While cutaneous (skin) PGs frequently show these MAPK-pathway mutations 16, studies on LCH from other anatomical sites have yielded strikingly different results.

• A 2018 study analyzing 28 periocular PGs (lesions on the eyelid and conjunctiva) failed to identify a single BRAF V600E mutation. The authors concluded that this mutation is "not a common driver" for lesions in this specific location.41
• Similarly, a 2019 study of oral PGs (from the mouth) also failed to find mutations in the hotspot regions of BRAF, KRAS, HRAS, NRAS, GNA11, or GNA14.42
• Most significantly, the oral PG study did find evidence that the MAPK/ERK pathway was activated, but this activation was occurring without the driver mutations seen in skin lesions.42

These contradictory findings (e.g.41 versus 16) do not invalidate the neoplastic model. Instead, they refine it, strongly suggesting that "Lobular Capillary Hemangioma" is a histological endpoint—a final common morphology—that can be reached via multiple, distinct molecular pathways. This leads to a "Two-Pathway" hypothesis: 1. Pathway 1 (Mutation-Driven Neoplasm): This model applies to many cutaneous and trauma-associated PGs. A somatic mutation (e.g., BRAF V600E) 18 acts as a constitutive, internal "on-switch." This leads to permanent MAPK pathway activation and the resulting LCH tumor. Because this "engine" is internal and permanent, these lesions "rarely resolve spontaneously" 1 and require surgical removal to be cured.6 2. Pathway 2 (Ligand-Driven Process): This model may apply to the oral and hormone-driven PGs. This is supported by the oral PG study that found pathway activation but no mutation.42 In this model, the "triggers" (e.g., pregnancy hormones 22, chronic gingival irritation 26) cause a temporary overproduction of external signaling molecules (ligands) like VEGF.22 These ligands flood the cell's receptors, "switching on" the MAPK pathway from the outside. This also leads to the LCH morphology, but the "engine" is external and temporary. This model perfectly explains why "granuloma gravidarum" (a classic "Pathway 2" lesion) "usually regress once they deliver their child".1 Once the external stimulus (the hormones) is removed, the "engine" shuts off, and the lesion naturally enters the involutionary (fibrotic) phase.

Section 6: Histopathological Divergence: LCH vs. Non-LCH

This molecular duality is mirrored by a morphological duality. A critical distinction exists within the capillary phase itself. Histopathological analysis reveals that not all PGs are identical. They can be classified into two distinct architectural subtypes: the Lobular Capillary Hemangioma (LCH) type and the Non-Lobular Capillary Hemangioma (Non-LCH) type.1 This morphological divergence strongly suggests "different evolutionary pathways" for the lesions.37

6.1. The LCH Type (Classic/Neoplastic Pattern)

This is the "classic" form, corresponding to the neoplastic model described in Section 4. It is defined by "proliferating blood vessels organized in lobular aggregates".37

• Architecture: It features distinct connective tissue septae separating the lobules.37
• Vessels: The vessels within the lobules typically have a "small luminal diameter".37
• Immunohistochemistry (IHC): A key distinguishing finding is that the perivascular mesenchymal cells (cells surrounding the vessels) are "$\alpha$SMA positive" (alpha-smooth muscle actin).37 This indicates the presence of myofibroblasts and a more organized, structured perivascular support system, which is characteristic of a true, well-differentiated hemangioma.

6.2. The Non-LCH Type (Reactive/Granulation Tissue Pattern)

This subtype "does not show any such organization".37 Its appearance is much closer to the lesion's "Cellular Phase" (Phase I).

• Architecture: It is described as a "high vascular proliferation resembling granulation tissue".37 There is "no aggregation" of vessels into lobules, and the stroma shows only "focal fibrous tissue" rather than organized septae.37
• Vessels: The blood vessels tend to have a "larger luminal diameter".37
• Immunohistochemistry (IHC): The corresponding IHC finding is that the perivascular mesenchymal cells are "$\alpha$SMA negative".37 This signifies a less organized, more primitive stroma, much like that seen in simple granulation tissue.

This LCH vs. Non-LCH distinction 37 is highly significant. It is very likely the microscopic manifestation of the "Two-Pathway" (neoplastic vs. reactive) hypothesis. The "LCH type" 37—with its organized, $\alpha$SMA-positive lobules—is the morphological correlate of the true "benign neoplasm" (Pathway 1). The "Non-LCH type" 37—which is explicitly described as "resembling granulation tissue" 37—is the morphological correlate of the "reactive" process (Pathway 2). This suggests that the single clinical diagnosis of "PG" is a "lump" diagnosis for at least two different, though related, pathobiological entities.

Table 2. Comparative Histopathological and Immunohistochemical Features of LCH and Non-LCH Subtypes

Feature LCH Type (Neoplastic Pattern) Non-LCH Type (Reactive Pattern) Vessel Organization Vessels organized in distinct "lobular aggregates".37 "No aggregation".37 High vascular proliferation "resembling granulation tissue".37 Stromal Architecture Connective tissue septae form between lobules.37 "Focal fibrous tissue".37 No organized septae. Vessel Luminal Diameter "Small".37 "Larger".37 Perivascular Cells (IHC) "$\alpha$SMA positive".37 (Myofibroblast-like, organized) "$\alpha$SMA negative".37 (Unorganized)

Section 7: Resolution and Maturation: The Involutionary (Fibrotic) Stage

7.1. Histological Markers of Healing and Regression

The Involutionary Phase (Phase III) represents the "end stage" of the lesion's life cycle, marking the transition out of the proliferative capillary stage. The primary histological marker of this phase is "extensive fibrosis".6 This represents the "final stage of regression".6 The stroma, which was edematous in Phase I 6 and fibromyxoid in Phase II 22, undergoes a profound change. It is replaced by "densely packed type I collagen".22 As this fibrosis progresses, the other cellular components of the capillary stage regress. The "inflammatory cells" and "myofibroblasts disappear" 22, and the vascular lobules shrink and are replaced by fibrous tissue. Biopsies of older, "mature" lesions are therefore described as having a much more prominent "fibrous character".4

7.2. Clinical Correlation: From Fleshy Papule to Fibrous Nodule

This histological fibrosis directly correlates with the clinical evolution of the lesion. The LCH/PG stops bleeding, loses its friability, and changes in appearance from a bright red, "fleshy" papule to a "paler pink colour" 1 and a firmer, non-bleeding, fibrous nodule. The likelihood of this spontaneous involution, however, is directly tied to the lesion's underlying etiology. For sporadic, cutaneous lesions, spontaneous resolution "rarely… occurs".1 The exception is "granuloma gravidarum".1 These hormone-driven lesions "usually go away after a pregnancy" or "regress once they deliver their child".1 This differential behavior is the key clinical proof that supports the "Two-Pathway" molecular hypothesis detailed in Section 5.

• The "Pathway 2" (Ligand-Driven) lesions, like granuloma gravidarum, have their external "engine" (pregnancy hormones) shut off post-partum. This allows them to naturally progress into the involutionary (fibrotic) phase.2
• The "Pathway 1" (Mutation-Driven) lesions have an internal, constitutive "engine" (e.g., a BRAF V600E mutation 18). This signal cannot be shut off. These lesions are "stuck" in the proliferative capillary stage and cannot enter this involutionary phase on their own. This is why sporadic PGs "rarely resolve spontaneously" 1 and require complete surgical destruction to be cured.6

Section 8: Diagnostic Implications and Conclusion

8.1. The Critical Role of Histopathological Examination

Given the clinical and histological complexity, a biopsy and "histologic examination" are considered required for all lesions that are removed.6 This is not merely an academic formality. It is an essential step for two primary reasons: 1. To confirm the diagnosis of Lobular Capillary Hemangioma and, if possible, identify its subtype (LCH vs. Non-LCH). 2. To definitively "rule out… melanomas or other malignant tumors" 6 that can clinically mimic LCH/PG.

8.2. Differential Diagnosis: The Malignant Mimics

The "capillary stage" of LCH/PG is a notorious "great mimic." Its clinical presentation of a rapidly growing, red, ulcerated, and bleeding nodule is a "red flag" for several malignant conditions.

• Amelanotic Melanoma: This is the most dangerous and critical differential diagnosis.6 A nodular amelanotic (non-pigmented) melanoma can be clinically indistinguishable from an LCH/PG. Both are rapidly growing, red, fleshy, and bleeding nodules. Misdiagnosing an amelanotic melanoma as a benign PG can be a fatal error, making histopathological confirmation essential.
• Angiosarcoma: Histologically, the "high cellularity and frequent mitotic activity" 39 of a rapidly growing LCH can be concerning. However, a pathologist can distinguish them. LCH is "circumscribed" (well-defined) and "lobular," features that are "inconsistent with angiosarcoma," which is a highly infiltrative, disorganized malignancy.39
• Kaposi Sarcoma: This is another vascular tumor that must be in the differential, as it also presents with vascular proliferation and an inflammatory infiltrate.29
• Other Mimics: The differential also includes basal cell carcinoma, squamous cell carcinoma 6, and other reactive oral lesions like peripheral giant cell granuloma (PGCG).14

The primary clinical importance of understanding the LCH "capillary stage" is not just in diagnosing LCH, but in ruling out its "great mimic," amelanotic melanoma.6 A clinician cannot reliably distinguish these two entities by eye. Therefore, the "capillary stage" of LCH presents a high-stakes diagnostic challenge, and the recommendation for "biopsy and histologic examination" 6 is an essential safety-net.

8.3. Pathological Basis for Clinical Management and Recurrence

The histopathology of the capillary stage is the definitive guide to treatment. The architecture of a polypoid mass 2 on a stalk containing "feeder vessels" 2 is the fundamental reason "recurrence is common" 1, especially after "inadequate treatment" 1 or "partial resection".2 Therefore, the treatment of choice, dictated by this pathology, is "complete primary excision" 2 or "excision with linear closure".6 These methods "offer the lowest recurrence rate" 6 because they ensure the entire base of the lesion, including the stalk and feeder vessels, is removed.15

8.4. Conclusion: Synthesizing the Capillary Stage

The "capillary/vascular stage" is the definitive, fully-realized, and clinically symptomatic phase of Lobular Capillary Hemangioma. It represents a critical transition in the lesion's life, evolving from a non-specific "cellular phase" (which resembles granulation tissue) 6 into a histologically distinct and organized entity defined by its "prominent lobular capillary arrangement".1 This stage is the morphological expression of a complex and sophisticated molecular pathogenesis. It is driven by a pro-angiogenic milieu rich in factors like VEGF 22 and, in a significant subset of cases, by the constitutive neoplastic activation of the MAPK pathway via somatic mutations in genes such as BRAF and HRAS.16 Furthermore, this capillary stage is not monolithic. It shows histopathological divergence into LCH (neoplastic) and Non-LCH (reactive-like) subtypes.37 This divergence likely corresponds to different underlying molecular drivers (e.g., mutation-driven vs. ligand-driven), which in turn explains the different clinical behaviors, such as the spontaneous regression of pregnancy tumors versus the persistence of sporadic cutaneous lesions.1 Clinically, this stage is defined by its rapid, friable, and hemorrhagic growth.35 This presentation creates a high-stakes diagnostic challenge, as it must be differentiated from malignant mimics, most notably amelanotic melanoma.6 Therefore, a comprehensive understanding of the capillary-vascular stage—from its clinical appearance to its lobular architecture and molecular drivers—is essential for accurate diagnosis, mandatory histopathological confirmation 34, and the selection of effective, curative treatment aimed at complete excision of its vascular base.6 Nguồn trích dẫn 1. Pyogenic granuloma – DermNet, truy cập vào tháng 11 11, 2025, https://dermnetnz.org/topics/pyogenic-granuloma 2. Pyogenic Granuloma – StatPearls – NCBI Bookshelf, truy cập vào tháng 11 11, 2025, https://www.ncbi.nlm.nih.gov/books/NBK556077/ 3. Pyogenic Granuloma: Symptoms, Causes & Treatment – Cleveland Clinic, truy cập vào tháng 11 11, 2025, https://my.clevelandclinic.org/health/diseases/22717-pyogenic-granuloma 4. Pyogenic granuloma – Wikipedia, truy cập vào tháng 11 11, 2025, https://en.wikipedia.org/wiki/Pyogenic_granuloma 5. Oral pyogenic granuloma: Various concepts of etiopathogenesis – PMC – NIH, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3303528/ 6. Pyogenic Granuloma, truy cập vào tháng 11 11, 2025, https://cdn-uat.mdedge.com/files/s3fs-public/Document/September-2017/074040229.pdf 7. Definition of pyogenic granuloma – NCI Dictionary of Cancer Terms, truy cập vào tháng 11 11, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pyogenic-granuloma 8. truy cập vào tháng 11 11, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lobular-capillary-hemangioma#:~:text=Listen%20to%20pronunciation,other%20places%20on%20the%20body. 9. Definition of lobular capillary hemangioma – NCI Dictionary of Cancer Terms, truy cập vào tháng 11 11, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lobular-capillary-hemangioma 10. Pyogenic Granulomas | Children's Hospital of Philadelphia, truy cập vào tháng 11 11, 2025, https://www.chop.edu/conditions-diseases/pyogenic-granulomas 11. Gastrointestinal Pyogenic Granuloma (Lobular Capillary Hemangioma): An Underrecognized Entity Causing Iron Deficiency Anemia – NIH, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4925958/ 12. Pyogenic granuloma of the gingiva: A misnomer? – A case report and review of literature, truy cập vào tháng 11 11, 2025, https://pubmed.ncbi.nlm.nih.gov/24174735/ 13. truy cập vào tháng 11 11, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pyogenic-granuloma#:~:text=(PY%2Doh%2DJEH%2D,quickly%20and%20bleed%20a%20lot. 14. Lobular Capillary Hemangioma in a Young Child: Diagnostic Dilemma and Management, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10562197/ 15. “Pyogenic Granuloma – Hyperplastic Lesion of the Gingiva: Case Reports”, truy cập vào tháng 11 11, 2025, https://opendentistryjournal.com/VOLUME/6/PAGE/153/ 16. Recurrent Alterations in the MAPK pathway in Sporadic Pyogenic Granuloma of Childhood | Acta Dermato-Venereologica, truy cập vào tháng 11 11, 2025, https://medicaljournalssweden.se/actadv/article/view/1119/7371 17. BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma – ResearchGate, truy cập vào tháng 11 11, 2025, https://www.researchgate.net/publication/282344496_BRAF_and_RAS_Mutations_in_Sporadic_and_Secondary_Pyogenic_Granuloma 18. BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma – PubMed, truy cập vào tháng 11 11, 2025, https://pubmed.ncbi.nlm.nih.gov/26802240/ 19. Recurrent Alterations in the MAPK pathway in Sporadic Pyogenic Granuloma of Childhood, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9558325/ 20. Pyogenic Granuloma Diagnosis and Management: A Practical … – NIH, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11398770/ 21. What is pyogenic granuloma? – Nicklaus Children's Hospital, truy cập vào tháng 11 11, 2025, https://www.nicklauschildrens.org/conditions/pyogenic-granuloma 22. Oral Pyogenic Granuloma: A Narrative Review – MDPI, truy cập vào tháng 11 11, 2025, https://www.mdpi.com/1422-0067/24/23/16885 23. Lobular capillary hemangioma – VisualDx, truy cập vào tháng 11 11, 2025, https://www.visualdx.com/visualdx/diagnosis/lobular+capillary+hemangioma?diagnosisId=51646&moduleId=11 24. Lobular capillary hemangioma – VisualDx, truy cập vào tháng 11 11, 2025, https://www.visualdx.com/visualdx/diagnosis/lobular-capillary-hemangioma?moduleId=11&diagnosisId=51646 25. Pyogenic granuloma Information | Mount Sinai – New York, truy cập vào tháng 11 11, 2025, https://www.mountsinai.org/health-library/diseases-conditions/pyogenic-granuloma 26. Causes of Pyogenic Granuloma – News-Medical, truy cập vào tháng 11 11, 2025, https://www.news-medical.net/health/Causes-of-Pyogenic-Granuloma.aspx 27. Lobular Capillary Hemangioma | American Journal of Neuroradiology, truy cập vào tháng 11 11, 2025, https://www.ajnr.org/ajnr-case-collections-diagnosis/lobular-capillary-hemangioma 28. An Uncommon Presentation of Pyogenic Granuloma – PMC – NIH, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7861056/ 29. Pyogenic Granuloma – A Common Benign Vascular Tumor with Variable Clinical Presentation: New Findings and Treatment Options – NIH, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5535648/ 30. Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation – PubMed, truy cập vào tháng 11 11, 2025, https://pubmed.ncbi.nlm.nih.gov/27116335/ 31. Pyogenic granuloma in patients treated with selective BRAF inhibitors – ResearchGate, truy cập vào tháng 11 11, 2025, https://www.researchgate.net/publication/297684032_Pyogenic_granuloma_in_patients_treated_with_selective_BRAF_inhibitors 32. Lobular Capillary Hemangioma (Pyogenic Granuloma) Condition, Treatments and Pictures for Infants – Skinsight, truy cập vào tháng 11 11, 2025, https://skinsight.com/skin-conditions/pyogenic-granuloma/infant/ 33. Pyogenic Granulomas – Dermatologic Disorders – Merck Manual Professional Edition, truy cập vào tháng 11 11, 2025, https://www.merckmanuals.com/professional/dermatologic-disorders/benign-skin-tumors-growths-and-vascular-lesions/pyogenic-granulomas 34. Pyogenic Granulomas – Dermatologic Disorders – MSD Manual Professional Edition, truy cập vào tháng 11 11, 2025, https://www.msdmanuals.com/professional/dermatologic-disorders/benign-skin-tumors-growths-and-vascular-lesions/pyogenic-granulomas 35. Simple, safe, and effective treatment for pyogenic granuloma – PMC – NIH, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10348791/ 36. Pyogenic Granuloma | The Atlas of Emergency Medicine, 5e, truy cập vào tháng 11 11, 2025, https://accessemergencymedicine.mhmedical.com/content.aspx?bookid=2969§ionid=250461921 37. The Histopathological Spectrum of Pyogenic Granuloma: A Case …, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4921146/ 38. The Histopathological Spectrum of Pyogenic Granuloma: A Case Series – PubMed, truy cập vào tháng 11 11, 2025, https://pubmed.ncbi.nlm.nih.gov/27382492/ 39. Pyogenic granuloma of labial mucosa: A misnomer in an anomolous site – PubMed Central, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3467924/ 40. Subcutaneous Lobular Capillary Hemangioma Presenting as a Facial Mass – PMC – NIH, truy cập vào tháng 11 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5964439/ 41. No BRAF V600E Mutation Identified in 28 Periocular Pyogenic Granuloma – PubMed, truy cập vào tháng 11 11, 2025, https://pubmed.ncbi.nlm.nih.gov/29406329/ 42. Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations – PubMed, truy cập vào tháng 11 11, 2025, https://pubmed.ncbi.nlm.nih.gov/31310691/ 43. No BRAF V600E Mutation Identified in 28 Periocular Pyogenic Granuloma, truy cập vào tháng 11 11, 2025, https://pure.johnshopkins.edu/en/publications/no-braf-v600e-mutation-identified-in-28-periocular-pyogenic-granu